12:00 AM
Jun 25, 2012
 |  BioCentury  |  Emerging Company Profile

LoneStar Heart: Straight to the heart

LoneStar Heart developing trio of technologies for advanced heart failure

Therapies for heart failure are palliative and aimed primarily at delaying pathological cardiac remodeling and progression to advanced disease. LoneStar Heart Inc. is developing a trio of technologies that it believes have the potential to restore the heart's structure and function, reversing disease progression.

President and COO Frank Ahmann said LoneStar's programs target patients with New York Heart Association (NYHA) Class II-III heart failure because "these patients are not optimally treated with pharmaceuticals and are not yet candidates for more invasive and expensive options such as a heart transplant, implantation of a left-ventricular assist device or cardiac resynchronization therapy."

Drugs used to treat heart failure include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta blockers and diuretics.

Still, 40-60% of patients die within five years of diagnosis, Ahmann told BioCentury.

LoneStar's lead program, Algisyl-LVR, is a biologically inert polymer that could improve cardiac function and reverse the deleterious effects of cardiac remodeling. The product is injected into the left ventricle...

Read the full 792 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >